Inno-Gene SA
WSE:IGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Inno-Gene SA
Cash from Financing Activities
Inno-Gene SA
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Inno-Gene SA
WSE:IGN
|
Cash from Financing Activities
zł895k
|
CAGR 3-Years
-29%
|
CAGR 5-Years
38%
|
CAGR 10-Years
33%
|
|
|
N
|
Nanogroup SA
WSE:NNG
|
Cash from Financing Activities
zł7.3m
|
CAGR 3-Years
127%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Cash from Financing Activities
zł1m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Cash from Financing Activities
-zł3.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Selvita SA
WSE:SLV
|
Cash from Financing Activities
-zł56.6m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Inno-Gene SA
Glance View
Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
See Also
What is Inno-Gene SA's Cash from Financing Activities?
Cash from Financing Activities
895k
PLN
Based on the financial report for Jun 30, 2024, Inno-Gene SA's Cash from Financing Activities amounts to 895k PLN.
What is Inno-Gene SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
33%
Over the last year, the Cash from Financing Activities growth was -72%. The average annual Cash from Financing Activities growth rates for Inno-Gene SA have been -29% over the past three years , 38% over the past five years , and 33% over the past ten years .
